Chinese ophthalmology company Ocumension has paid for exclusive rights to develop and commercialize Nicox’s (Euronext: Paris) NCX 470 in China.
The news sent shares in France-based Nicox soaring on Monday, with the price up by 14% by mid-afternoon.
NCX 470 is being developed for patients with glaucoma or ocular hypertension. Ocumension will pay a one-time upfront payment of 3 million euros ($3.4 million) and a further 2.5 million euros when Nicox initiates a Phase III clinical study with NCX 470 outside the territory of this agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze